Prospective Study for the Application of Cytosorb® in Critically Ill Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2023-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation, rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis, polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly retrospectively, there are no data on real-time elimination performance and saturation kinetics during the course of treatment. These questions should be answered by the present study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

NCT04344080

COVID-19

COMPLETED NA

Adjuvant Therapy With CytoSorb in Refractory Septic Shock

NCT04013269

Septic Shock

UNKNOWN NA

Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis

NCT00559130

Acute Respiratory Distress Syndrome Acute Lung Injury Sepsis

COMPLETED NA

Cytokine Adsorption in Severe, Refractory Septic Shock

NCT04910893

Septic Shock Cytokine Storm

COMPLETED NA

Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.

NCT04226430

Sepsis Cytokine Storm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhabdomyolysis Acute Liver Injury Cytokine Storm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cytosorb therapy

blood samples are taken before and after the cytokine adsorber at given times

Group Type OTHER

Cytosorb therapy

Intervention Type DEVICE

Start of Cytosorb therapy is at the discretion of the attending physician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytosorb therapy

Start of Cytosorb therapy is at the discretion of the attending physician

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* intensive care therapy
* hyperinflammation or acute liver dysfunction or rhabdomyolysis
* need of continuous renal replacement therapy
* treatment with Cytosorb (decision of the attending physician)